Thymosin Alpha-1 Information & Coordination for Licensed U.S. Clinics
Thymosin alpha-1 (Ta1) is a 28-amino-acid peptide. FDA notes that thymalfasin is a chemically synthesized version of Ta1. In its compounding review, FDA evaluated Ta1 free base and Ta1 acetate as separate bulk drug substances.
FDA reviewed both substances in 2024 as part of its section 503A bulk-drug-substance process. Neither is a component of an FDA-approved drug.
Phoenix Meds Inc. supports licensed healthcare organizations with credential review, documentation, publicly available regulatory information, and administrative coordination.
We are not a pharmacy, medical practice, manufacturer, prescriber, or dispensing entity.
What Clinics Should Know About Thymosin Alpha-1
Thymosin alpha-1 should not be presented as an FDA-approved treatment.
FDA evaluated thymosin alpha-1 free base and thymosin alpha-1 acetate as separate bulk drug substances. The agency notes that the two forms are chemically distinct and may have different physical, pharmacokinetic, safety, or effectiveness characteristics.
FDA reviewed proposed uses involving hepatitis B and C, HIV, COVID-19, vaccine response, several cancers, sepsis, infections following hematopoietic stem-cell transplantation, COPD, and ME/CFS. The fact that a use was evaluated does not mean FDA approved thymosin alpha-1 for that condition.
Phoenix does not promote thymosin alpha-1 for immune enhancement, infection treatment, cancer support, vaccine response, autoimmune conditions, or other clinical outcomes.
Current FDA and Compounding Status
The nomination involving thymosin alpha-1-related bulk drug substances was withdrawn, but FDA continued evaluating thymosin alpha-1 free base and thymosin alpha-1 acetate on its own initiative.
FDA found that neither substance has an applicable USP/NF drug-substance monograph and neither is a component of an FDA-approved drug. The agency concluded that its evaluation criteria weighed against placing either substance on the 503A Bulks List.
At the December 2024 Pharmacy Compounding Advisory Committee meeting, FDA proposed that neither thymosin alpha-1 free base nor thymosin alpha-1 acetate be included on the 503A Bulks List. The committee voted 4–17 against inclusion of each substance.
That advisory process should not be described as a final FDA rule by itself. FDA explains that advisory-committee recommendations are non-binding and that final determinations occur after the agency completes its review.
A pharmacy’s 503A status or a 503B outsourcing facility’s registration also does not automatically establish that a particular bulk drug substance may be used in compounding. Federal law places separate conditions on bulk substances under each framework.
Why Product Identity Matters
FDA’s review found inconsistent information in the original nomination regarding whether thymosin alpha-1 free base or thymosin alpha-1 acetate was intended.
FDA treats these as separate bulk drug substances rather than interchangeable descriptions.
FDA also notes that thymalfasin is a chemically synthesized version of thymosin alpha-1, while Zadaxin is a finished drug product marketed outside the United States and should not be treated as interchangeable with the Ta1 bulk drug substances evaluated by FDA.
For clinics, that makes the underlying documentation important. A product name alone does not establish FDA approval, compounding eligibility, quality, or clinical suitability.
Phoenix can help organize available information and identify questions that need further professional review.
How Phoenix Meds Supports Licensed Clinics
Our role is administrative.
Licensed healthcare organizations may use Phoenix for help reviewing professional credentials, organizing documentation, checking publicly available licensing and regulatory records, and identifying gaps or inconsistencies that require further review.
We can also help distinguish documented information from marketing or supplier claims so the appropriate clinical, regulatory, or legal professional can review the remaining questions.
Our administrative review is not FDA approval, pharmacy accreditation, a clinical recommendation, or a legal opinion.
Safety and Documentation Considerations
FDA’s current safety materials identify potential concerns involving compounded thymosin alpha-1.
The agency says compounded thymosin-alpha-1 may present significant immunogenicity risk for certain routes of administration and may involve complexities related to peptide impurities and API characterization. FDA also states that available safety information is inadequate to fully understand the extent of potential safety issues.
Phoenix does not manufacture, test, compound, dispense, ship, or take custody of thymosin alpha-1. We also do not certify its purity, potency, sterility, authenticity, safety, or clinical suitability.
Thymosin Alpha-1 Administrative Coordination for Licensed Clinics
Licensed U.S. healthcare organizations may contact Phoenix Meds Inc. regarding credential review, documentation, and publicly available regulatory information concerning thymosin alpha-1. An administrative inquiry is not a medication order and does not establish FDA approval, compounding eligibility, product availability, or clinical appropriateness.
Clinic Verification
Documentation Review
Phoenix may help organize available records and current regulatory information so the clinic can identify questions requiring further review.
Licensed Parties
Prescribing, compounding, dispensing, distribution, storage, shipping, and other regulated medication activities remain with the parties legally authorized and responsible for performing them.
Frequently Asked Questions
Is thymosin alpha-1 FDA approved?
FDA’s 2024 briefing states that thymosin alpha-1 free base and thymosin alpha-1 acetate are not components of FDA-approved drugs.
Is thymosin alpha-1 on the 503A Bulks List?
FDA evaluated both the free-base and acetate forms and proposed that neither be included. At the December 2024 advisory-committee meeting, the committee voted against inclusion of both substances. Clinics should verify current FDA status before relying on any compounding pathway.
Are thymosin alpha-1 free base and acetate the same substance?
No. FDA treats them as separate bulk drug substances with distinct chemical characteristics.
Does Phoenix Meds compound or dispense thymosin alpha-1?
No. Phoenix does not compound, manufacture, dispense, test, ship, or take custody of thymosin alpha-1.
What can Phoenix Meds help clinics with?
Our role is administrative and may include credential review, documentation organization, review of publicly available regulatory information, and professional communication.
Does Phoenix Meds provide dosing or treatment protocols?
No. We do not provide patient-specific dosing, treatment protocols, or clinical recommendations.
Does Phoenix Meds guarantee quality or safety?
No. Phoenix does not test thymosin alpha-1 or certify its purity, potency, sterility, authenticity, safety, or clinical suitability.
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, outsourcing facility, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It does not present thymosin alpha-1 as an FDA-approved treatment and does not establish that a particular compounding or distribution pathway is available or permitted.
Regulatory References
- December 4, 2024 Pharmacy Compounding Advisory Committee
- Thymosin Alpha-1-Related Bulk Drug Substances — FDA Briefing Document
- December 4, 2024 Pharmacy Compounding Advisory Committee — Final Summary Minutes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act